The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InFulgent Genetics (NASDAQ: FLGT) has officially completed the acquisition of Bako Diagnostics and StrataDx laboratories, following an agreement reached in late 2025. The transaction, which was initially announced on December 22, 2025, reached its final closure on March 17, 2026. These acquired entities are recognized specialists in the fields of pathology and dermatopathology services, providing a significant boost to Fulgent's clinical capabilities. This strategic move is designed to broaden Fulgent's laboratory services portfolio and enhance its footprint in specialized diagnostic markets. Analysts view the completion of this deal as a positive development that is likely to bolster the company's revenue streams within the healthcare sector. The integration of these premier laboratories aligns with Fulgent’s long-term growth strategy in the evolving diagnostics industry.